Skip to Main content Skip to Navigation
New interface
Journal articles

Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium

Document type :
Journal articles
Complete list of metadata

https://hal-amu.archives-ouvertes.fr/hal-03625350
Contributor : Nicolas André Connect in order to contact the contributor
Submitted on : Wednesday, March 30, 2022 - 6:29:25 PM
Last modification on : Friday, October 14, 2022 - 3:53:21 AM

Identifiers

Citation

Claudia Pasqualini, Jonathan Rubino, Caroline Brard, Lydie Cassard, Nicolas André, et al.. Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium. European Journal of Cancer, 2021, 150, pp.53-62. ⟨10.1016/j.ejca.2021.03.032⟩. ⟨hal-03625350⟩

Share

Metrics

Record views

21